Loading organizations...
Loading organizations...
Biopharmaceutical company developing tumor targeting and immunotherapy drug
BlissBio has raised $61.3M across 1 funding round.
BlissBio has raised $61.3M in total across 1 funding round.
BlissBio has raised $61.3M in total across 1 funding round.
BlissBio's investors include Highfields Capital Management, Cormorant Asset Management, Darren Cai, VMS Group.
BlissBio has raised $61.3M across 1 funding round. Most recently, it raised $61.3M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 16, 2021 | $61.3M Series B | Highfields Capital Management | Cormorant Asset Management, Darren Cai, VMS Group |